Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6PO49)

Drug Name

[3H]NFPS Drug Info

Synonyms

405225-21-0; CHEMBL26512; A1-01880; N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine; n-[3-([1,1-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-n-methylglycine; 2-((3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl)(methyl)amino)acetic acid; [3H]-NFPS; AC1NSKCW; SCHEMBL427134; GTPL4620; GTPL4619; CTK8E8383; DTXSID30415522; MolPort-023-276-580; KS-000000NE; BCP21210; BCP17140; ( inverted exclamation

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5311283
CAS Number: CAS 405225-21-0
TTD Drug ID: DM6PO49

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glycine transporter GlyT-1 (SLC6A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R1678	DM4K9WH	Schizophrenia	6A20	Phase 3	[3]
BI 425809	DMH3XDR	Schizophrenia	6A20	Phase 3	[4]
Iclepertin	DM83JCK	Schizophrenia	6A20	Phase 3	[5]
AMG 747	DMWPGB8	Schizophrenia	6A20	Phase 2	[6]
ORG-25935	DMWN2EC	Psychotic disorder	6A20-6A25	Phase 2	[7]
PF-3463275	DMO02LU	Schizophrenia	6A20	Phase 2	[6]
GlyT1 PET radiotracers	DMCKZUT	Schizophrenia	6A20	Phase 1	[8]
ALX-5407	DMLJWPN	Schizophrenia	6A20	Phase 1	[9]
JNJ-17305600	DMMI4XR	Schizophrenia	6A20	Phase 1	[2]
DCCCyB	DMQ8ACY	Schizophrenia	6A20	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycine transporter GlyT-1 (SLC6A9)	TTHJTF7	SC6A9_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4619).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
3	Clinical pipeline report, company report or official report of Roche (2009).
4	Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201.
5	Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia. J Pharmacol Exp Ther. 2022 Aug;382(2):223-232.
6	Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85.
7	The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8.
8	Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Med Chem J. 2010; 4: 10-19.
9	ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001 Dec;60(6):1414-20.
10	Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. ACS Med Chem Lett. 2010 October 14; 1(7): 350-354.